Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.61 |
| ▸ | SRC | P12931 | 4/20 | 0.61 |
| ▸ | KDR | P35968 | 4/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.58 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356381 | 0.76 | KDR (0.52) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL5348818 | 0.76 | CSNK1E (0.44) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL5354206 | 0.76 | BRAF (0.54) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL1647214 | 0.75 | KDR (0.72) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL5352200 | 0.74 | IRAK4 (0.42) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL5698604 | 0.74 | CSNK1D (1.00) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL5257540 | 0.74 | CSNK1D (1.00) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL15070210 | 0.73 | BRAF (0.56) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL5356733 | 0.73 | CSNK1D (0.38) | BRAFSRCKDRMAPK14CSNK1D | |
| SCHEMBL14839424 | 0.72 | BRAF (1.00) | BRAFSRCKDRMAPK14CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| CN-100519552-C | Pyrazole compounds | UBE INDUSTRIES (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| CN-1684953-A | Pyrazole compounds | UBE INDUSTRIES (JP) | 2005-10-19 | — | — | CN | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | BRAF 2044/4885SRC 3264/4885KDR 534/4885 |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | BRAF 19/4885SRC 216/4885KDR 813/4885 |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | BRAF 2413/4885SRC 3785/4885KDR 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.